- Home
- MESO vs ARR Comparison
MESO vs ARR Comparison
Compare MESO & ARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- ARR
- Stock Information
- Founded
- MESO 2004
- ARR 2008
- Country
- MESO Australia
- ARR United States
- Employees
- MESO N/A
- ARR N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- ARR Real Estate Investment Trusts
- Sector
- MESO Health Care
- ARR Real Estate
- Exchange
- MESO Nasdaq
- ARR Nasdaq
- Market Cap
- MESO 1.3B
- ARR 1.4B
- IPO Year
- MESO N/A
- ARR N/A
- Fundamental
- Price
- MESO $15.81
- ARR $15.19
- Analyst Decision
- MESO Buy
- ARR Hold
- Analyst Count
- MESO 4
- ARR 5
- Target Price
- MESO $18.00
- ARR $16.00
- AVG Volume (30 Days)
- MESO 148.6K
- ARR 4.9M
- Earning Date
- MESO 09-02-2025
- ARR 07-23-2025
- Dividend Yield
- MESO N/A
- ARR 18.96%
- EPS Growth
- MESO N/A
- ARR N/A
- EPS
- MESO N/A
- ARR N/A
- Revenue
- MESO $5,670,000.00
- ARR $20,589,000.00
- Revenue This Year
- MESO $177.23
- ARR $378.40
- Revenue Next Year
- MESO $314.04
- ARR $36.52
- P/E Ratio
- MESO N/A
- ARR N/A
- Revenue Growth
- MESO N/A
- ARR N/A
- 52 Week Low
- MESO $6.00
- ARR $13.18
- 52 Week High
- MESO $22.00
- ARR $21.08
- Technical
- Relative Strength Index (RSI)
- MESO 58.97
- ARR 41.49
- Support Level
- MESO $14.68
- ARR $14.60
- Resistance Level
- MESO $16.38
- ARR $15.14
- Average True Range (ATR)
- MESO 0.44
- ARR 0.30
- MACD
- MESO -0.14
- ARR -0.06
- Stochastic Oscillator
- MESO 67.05
- ARR 25.65
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.